Prognostické faktory přežití u pacientů s hepatocelulárním karcinomem léčených pomocí transarteriální chemoembolizace

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Prognostic Survival Factors of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
Authors

ROHAN Tomáš UHER Michal MATKULČÍK Peter ZAVADIL Jan OSTŘÍŽKOVÁ Lenka KISS Igor ANDRAŠINA Tomáš VÁLEK Vlastimil

Year of publication 2020
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.linkos.cz/casopis-klinicka-onkologie/2020-07-15-3/prognosticke-faktory-preziti-u-pacientu-s-hepatocelularnim-karcinomem-lecenych-p/
Doi http://dx.doi.org/10.14735/amko2020214
Keywords hepatocellular carcinoma; transarterial chemoembolization; survival analysis; risk factors
Description Purpose: Identification of prognostic survival factors of hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) in a single center in 2005–2018. Background: Transarterial chemoembolization in hepatocellular carcinoma is indicated in Barcelona Liver Cancer Clinic (BLCC) stage B. This stage includes a very large group of patients unsuitable for curative treatment, who are in a good clinical condition and do not show extra-hepatic spread. The aim of this retrospective analysis is to identify factors influencing patient survival and to divide the patients into subgroups based on these risk factors. Materials and methods: All patients with HCC indicated for TACE in complex oncological center in 2005–2018 were included in the analysis. The survival rates from the 1st TACE were evaluated in relation to HCC on computed tomogra-phy/magnetic resonance prior to the 1st TACE (size of the biggest lesion, single/multiple lesions, unilobar/bilobar involvement), presence and severity of liver disease (cirrhosis, Child-Pugh, portal vein thrombosis) and a combination of other invasive treatment (resection, percutaneous ablation) (single and multivariate analysis). The survival of HCC patients was compared according to the year of the dia gnosis and the year of the 1st TACE (log-rank test). Results: Out of 382 patients, 157 (29 women) of them were treated with TACE (540 TACEs in total, median 3 TACEs per patient). The most important risk factors for survival were the presence of portal vein thrombosis (hazard ratio (HR) = 3.279), bilobar involvement (HR = 2.257), lesion size (HR = 1.125/cm) and Child-Pugh B in chronic liver disease (HR = 1.922). Based on these risk factors, the patients were divided into 3 prognostic groups with different median survival (52.1 vs. 21.5 vs. 9.0 months). Conclusion: Based on the retrospective analysis, predictive factors of HCC survival after TACE were identified and the patients were divided into 3 prognostic groups based on these factors.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info